Richard Drury
Topline Summary and Update
Having taken a look at Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) and coming away cautious just after a surge in value, the stock value more than doubled over the rest of 2024 before crashing
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
Summary
- Corbus Pharmaceuticals Holdings' pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages.
- The company’s financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding.
- Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep drop unrelated to CRBP’s own data.
- Given the improved valuation and contrarian opportunity, I now rate CRBP a 'Buy' as a speculative addition to a diversified portfolio.
I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CRBP over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.